Clinical trial
A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
NCT04856085 is registered in ClinicalTrials.gov with Vir Biotechnology, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
- Lead sponsor
- Vir Biotechnology, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 11, 2021
- Completion date
- March 16, 2026
- Enrollment
- 244 (actual)
- Sites
- 37
Conditions
As the registry lists them; a condition with its own page is linked.